Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vir Biotechnology, Inc. - Common Stock
(NQ:
VIR
)
9.135
-0.865 (-8.65%)
Streaming Delayed Price
Updated: 1:27 PM EST, Feb 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vir Biotechnology, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
February 25, 2026
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Proposed Public Offering of Common Stock
February 24, 2026
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
February 23, 2026
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
February 09, 2026
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
January 12, 2026
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
December 16, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
November 19, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
November 09, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
November 07, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 05, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
November 03, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
October 22, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
October 09, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
October 07, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
August 25, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 06, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
August 06, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
July 31, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
July 24, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
July 22, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
May 28, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
May 20, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
May 12, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
May 09, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 07, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
April 30, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
April 24, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
March 13, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
